Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
1. A method for treating a CD30-expressing hematologic cancer in a human subject, the method comprising administering to a subject in need thereof a dose of a pharmaceutical composition comprising cAC10-MC-vc-PAB-MMAE antibody-drug conjugate, wherein the administered dose of cAC10-MC-vc-PAB-MMAE antibody-drug conjugate is 1.2 mg/kg of the subject's body weight and the pharmaceutical composition is administered once every two weeks,
and wherein the CD30-expressing hematologic cancer is Hodgkin Lymphoma.
2. The method of claim 1 , wherein the human subject is newly diagnosed and has not previously been treated for the CD30-expressing hematologic cancer.
3. The method of claim 1 , wherein the pharmaceutical composition is administered for two or more treatment cycles.
4. The method of claim 3 , wherein the pharmaceutical composition is administered for 3 or more treatment cycles.
5. The method of claim 3 , wherein the pharmaceutical composition is administered for 4 or more treatment cycles.
6. The method of claim 3 , wherein the pharmaceutical composition is administered for 5 or more treatment cycles.
7. A method for treating a CD30-expressing hematologic cancer in a human subject, the method comprising administering to a subject in need thereof a dose of a pharmaceutical composition comprising cAC10-MC-vc-PAB-MMAE antibody-drug conjugate, wherein the administered dose of cAC10-MC-vc-PAB-MMAE antibody-drug conjugate is 1.2 mg/kg of the subject's body weight and the pharmaceutical composition is administered once every two weeks,
and wherein the average number of MMAE molecules per cAC10 antibody of the cAC10-MC-vc-PAB-MMAE antibody-drug conjugate in the pharmaceutical composition is about 4.
8. The method of claim 7 , wherein the human subject is newly diagnosed and has not previously been treated for the CD30-expressing hematologic cancer.
9. The method of claim 7 , wherein the pharmaceutical composition is administered for two or more treatment cycles.
10. The method of claim 7 , wherein the pharmaceutical composition is administered for 3 or more treatment cycles.
11. The method of claim 7 , wherein the pharmaceutical composition is administered for 4 or more treatment cycles.
12. The method of claim 7 , wherein the pharmaceutical composition is administered for 5 or more treatment cycles.
13. A method for treating a CD30-expressing hematologic cancer in a human subject, the method comprising administering to a subject in need thereof a dose of a pharmaceutical composition comprising (i) cAC10-MC-vc-PAB-MMAE antibody-drug conjugate, wherein the administered dose of cAC10-MC-vc-PAB-MMAE antibody-drug conjugate is 1.2 mg/kg of the subject's body weight and the pharmaceutical composition is administered once every two weeks,
wherein the CD30-expressing hematologic cancer is Hodgkin Lymphoma, and
wherein the average number of MMAE molecules per cAC10 antibody of the cAC10-MC-vc-PAB-MMAE antibody-drug conjugate in the pharmaceutical composition is about 4.
14. The method of claim 13 , wherein the human subject is newly diagnosed and has not previously been treated for the CD30-expressing hematologic cancer.
15. The method of claim 13 , wherein the pharmaceutical composition is administered for two or more treatment cycles.
16. The method of claim 13 , wherein the pharmaceutical composition is administered for 3 or more treatment cycles.
17. The method of claim 13 , wherein the pharmaceutical composition is administered for 4 or more treatment cycles.
18. The method of claim 13 , wherein the pharmaceutical composition is administered for 5 or more treatment cycles.